Archer Materials (ASX:AXE) said its biochip program remains on track to deliver a laboratory demonstrator for sensing blood potassium in patients with chronic kidney disease, a key step before external trials, according to a Friday filing with the Australian bourse.
Shares of the company fell past 3% in recent Friday trade.